Literature DB >> 2415419

Influence of aprotinin on insulin absorption and subcutaneous blood flow in type 1 (insulin-dependent) diabetes.

B Linde, R Gunnarsson.   

Abstract

Ten normal-weight Type 1 (insulin-dependent) diabetic patients (12 h postprandial) with normal insulin requirement were given 125I-labelled soluble insulin (10 U) in the thigh together with aprotinin (10000 KIU) or its diluent on two consecutive mornings. Disappearance of 125I-radioactivity was followed continuously for 3 h by external detection and plasma free insulin measured by radioimmunoassay. Subcutaneous blood flow following aprotinin or diluent was studied concomitantly in the contralateral thigh by external monitoring of locally injected 133Xenon. Plasma free insulin increased significantly faster (p less than 0.05) and the insulin area under the curve was significantly (p less than 0.05) greater during the first hour after injection of insulin with aprotinin. Subcutaneous blood flow (rate constants for 133Xenon) was significantly higher with aprotinin (p less than 0.05), the highest flow occurring early after injection. In conclusion, subcutaneously injected soluble insulin is more rapidly absorbed by addition of aprotinin to the insulin solution in Type 1 diabetes. Blood flow increase at the injection site may explain part of this effect.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2415419     DOI: 10.1007/bf00291968

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  15 in total

1.  Measurement of regional circulation by the local clearance of radioactive sodium.

Authors:  S S KETY
Journal:  Am Heart J       Date:  1949-09       Impact factor: 4.749

2.  Adipose tissue blood flow and insulin disappearance from subcutaneous tissue.

Authors:  K Kølendorf; J Bojsen; S L Nielsen
Journal:  Clin Pharmacol Ther       Date:  1979-05       Impact factor: 6.875

3.  Measurement of cutaneous blood flow by freely diffusible radioactive isotopes. Methodological studies on the washout of krypton-85 and xenon-133 from the cutaneous tissue in man.

Authors:  P Sejrsen
Journal:  Dan Med Bull       Date:  1971-05

4.  Blood flow through human adipose tissue determined with radioactive xenon.

Authors:  O A Larsen; N A Lassen; F Quaade
Journal:  Acta Physiol Scand       Date:  1966-03

5.  The effect of aprotinin on the absorption of subcutaneously injected regular insulin in normal subjects.

Authors:  M Berger; H J Cüppers; P A Halban; R E Offord
Journal:  Diabetes       Date:  1980-01       Impact factor: 9.461

6.  The absorption of subcutaneously injected short-acting soluble insulin: influence of injection technique and concentration.

Authors:  P Hildebrandt; L Sestoft; S L Nielsen
Journal:  Diabetes Care       Date:  1983 Sep-Oct       Impact factor: 19.112

7.  Importance of insulin absorption, subcutaneous blood flow, and residual beta-cell function in insulin therapy.

Authors:  T Lauritzen; C Binder; O K Faber
Journal:  Acta Paediatr Scand Suppl       Date:  1980

8.  Determination of free and total insulin and C-peptide in insulin-treated diabetics.

Authors:  H Kuzuya; P M Blix; D L Horwitz; D F Steiner; A H Rubenstein
Journal:  Diabetes       Date:  1977-01       Impact factor: 9.461

9.  Subcutaneous aprotinin causes local hyperaemia. A possible mechanism by which aprotinin improves control in some diabetic patients.

Authors:  G Williams; J C Pickup; S Bowcock; E Cooke; H Keen
Journal:  Diabetologia       Date:  1983-02       Impact factor: 10.122

10.  Diabetes responsive to intravenous but not subcutaneous insulin: effectiveness of aprotinin.

Authors:  G R Freidenberg; N White; S Cataland; T M O'Dorisio; J F Sotos; J V Santiago
Journal:  N Engl J Med       Date:  1981-08-13       Impact factor: 91.245

View more
  4 in total

1.  Aprotinin on insulin absorption and subcutaneous blood flow.

Authors:  G Williams; J Pickup
Journal:  Diabetologia       Date:  1986-03       Impact factor: 10.122

2.  The influence of aprotinin on regional absorption of soluble human insulin.

Authors:  D R Owens; J P Vora; J Birtwell; S Luzio; T M Hayes
Journal:  Br J Clin Pharmacol       Date:  1988-04       Impact factor: 4.335

3.  Lack of pharmacological effect of subcutaneous octreotide in an insulin-dependent diabetic patient: reversal after mixing with aprotinin.

Authors:  M Lunetta; M Di Mauro; R Le Moli
Journal:  J Endocrinol Invest       Date:  1997-06       Impact factor: 4.256

4.  Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen.

Authors:  F S Nielsen; L N Jørgensen; M Ipsen; A I Voldsgaard; H H Parving
Journal:  Diabetologia       Date:  1995-05       Impact factor: 10.122

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.